NFL BIOSCIENCES announcing that it has entered into a partnership to develop NFL-101, the company's drug candidate for smoking cessation, for the Indian market with Themis Medicare Ltd. Themis Medicare Limited (Themis) submitted an IND (Investigational New Drug) application for a Phase II /III clinical trial to the Central Drugs Standard Control Organization (CDSCO), the National Regulatory Authority of India (NRA). India has approximately 267 Million smokers, and their options for smoking cessation are very limited. Once the study is approved, the clinical trial will be conducted in India, targeting 334 smokers.

The cost of the process, from submission to completion of the study, will be carried out by Themis Medicare. Themis will purchase from NFL Biosciences NFL-101 Active Pharmaceutical Ingredient (API). NFL will also receive double digit royalties on sales.